Cancer Research Landon Prizes for Basic and Translational Cancer Research  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 51, 3159-3163, June 15, 1991]
© 1991 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Neefe, J. R.
Right arrow Articles by Glass, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neefe, J. R.
Right arrow Articles by Glass, J.

Abrogation of Interferon-induced Resistance to Interferon-activated Major Histocompatibility Complex-unrestricted Killers by Treatment of a Melanoma Cell Line with 5-Fluorouracil1

John R. Neefe2 and Judy Glass

Veterans Administration Medical Center and the Department of Medicine and the Markey Cancer Center, University of Kentucky Medical Center, Lexington, Kentucky 40536

Advanced cancer responds clinically to combined therapy with recombinant interferon-{alpha} and 5-fluorouracil. Although the two agents may interact in the biosynthetic pathway for thymidine, we investigated, as an alternative mechanism, the regulation of susceptibility of the A375 human melanoma to natural killers activated by interferon. A375 were preincubated with 5-fluorouracil, interferon, or both sequentially prior to assay as targets for cell-mediated killing. Pretreatment of A375 with interferon decreased apparent lytic efficiency. 5-Fluorouracil alone increased the susceptibility of A375 to killing. Pretreatment of targets with 5-fluorouracil abrogated the resistance normally induced by interferon pretreatment. Thus, 5-fluorouracil modulates certain immunoregulatory effects of interferon-{alpha}. Thymidine does not block the effect of 5-fluorouracil. While fluorodeoxyuridine is relatively ineffective in this system, fluorouridine is more effective than 5-fluorouracil in abrogating the effect of interferon. These data suggest important interactions of 5-fluorouracil and interferon in pathways for protein synthesis. It is known that interferon both increases the activity of natural killers and increases resistance of tumors to natural killers. We have shown that 5-fluorouracil, by blocking the resistance, may allow the augmented natural killing to be effective. This observation provides an alternate hypothesis for the clinical activity of 5-fluorouracil and interferon in combination.

1 Supported by the Department of Veterans Affairs.

2 To whom requests for reprints should be addressed, at Markey Cancer Center, University of Kentucky Medical Center, Lexington, KY 40536-0093.

Received 1/14/91. Accepted 4/ 5/91.




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
A.-S.A. Ismail, C. J. Van Groeningen, A. Hardcastle, Q.-F. Ren, G. W. Aherne, F. Geoffroy, C. J. Allegra, and J. L. Grem.
Modulation of Fluorouracil Cytotoxicity by Interferon-alpha and -gamma
Mol. Pharmacol., February 1, 1998; 53(2): 252 - 261.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1991 by the American Association for Cancer Research.